Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9650550 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL15325990 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL15326926 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL12522087 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL8723430 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL15325988 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL13881475 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL13881471 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL15325987 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL15325991 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110761078-B | Preparation method and application of black body material | 中国科学技术大学 | 2021-04-23 | — | — | CN | claimed |
| CN-110761078-A | Preparation method and application of black body material | 中国科学技术大学 | 2020-02-07 | — | — | CN | claimed |
| US-20230400764-A1 | ORGANOMETALLIC COMPOUND COMPRISING A METAL COMBINED WITH AT LEAST ONE LIGAND CONTAINING FOUR OR MORE FLUORINE ATOMS, RESIST COMPOSITION COMPRISING THE SAME, AND METHOD OF FABRICATING SEMICONDUCTOR DEVICE USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-12-14 | — | — | US | disclosed |
| US-20230240128-A1 | COMPOUNDS FOR FORMING A PATTERNING COATING AND DEVICES INCORPORATING SAME | OTI LUMIONICS INC. (CA) | 2023-07-27 | — | — | US | disclosed |
| US-11273583-B2 | Polyorganosiloxane-based composition intended for tyre moulding/stripping | ELKEM SILICONES FRANCE SAS (FR) | 2022-03-15 | — | — | US | disclosed |
| WO-2021094588-A1 | USE OF PERFLUORO-N-OCTANE FOR PIEZO-MEDIATED INTRACYTOPLASMIC SPERM INJECTION | Vitrolife Sweden Aktiebolag (SE) | 2021-05-20 | — | — | WO | disclosed |
| CN-110761078-B | Preparation method and application of black body material | 中国科学技术大学 | 2021-04-23 | — | — | CN | disclosed |
| US-10906908-B2 | Ionic liquid, lubricating agent, and magnetic recording medium | DEXERIALS CORPORATION (JP) | 2021-02-02 | — | — | US | disclosed |
| CN-110761078-A | Preparation method and application of black body material | 中国科学技术大学 | 2020-02-07 | — | — | CN | disclosed |
| US-20180251468-A1 | Ionic Liquid, Lubricating Agent, and Magnetic Recording Medium | DEXERIALS CORP (JP) | 2018-09-06 | — | — | US | disclosed |
| US-20150353558-A1 | Ionic Liquid, Lubricating Agent, and Magnetic Recording Medium | DEXERIALS CORPORATION (JP) | 2015-12-10 | — | — | US | disclosed |
| US-7678918-B2 | Intermediates for imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
| US-7335773-B2 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335773-B2 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-5668251-A | Preparation of co-prepolymers from mono-substituted fluorinated monomers and tetrahydrofuran | AEROJET-GENERAL CORPORATION (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0151697-B1 | METHOD FOR PURIFYING A MIXTURE OF PERFLUOROCARBONS | ADAMANTECH, INC. (US) | 1988-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | IFNG, IRF3, MAVS | LMNA 2779/4885THRB 3595/4885CA2 4509/4885 |
| US-10906908-B2 | Ionic liquid, lubricating agent, and magnetic recording medium | MUC1, JAK1, JAK3 | LMNA 2468/4885THRB 3275/4885CA2 507/4885 |
| US-20230240128-A1 | COMPOUNDS FOR FORMING A PATTERNING COATING AND DEVICES INCORPORATING SAME | NONO, EPHA4, EPHA6 | LMNA 4297/4885THRB 4260/4885CA2 1412/4885 |
| US-20230400764-A1 | ORGANOMETALLIC COMPOUND COMPRISING A METAL COMBINED WITH AT LEAST ONE LIGAND CONTAINING FOUR OR MORE FLUORINE ATOMS, RESIST COMPOSITION COMPRISING THE SAME, AND METHOD OF FABRICATING SEMICONDUCTOR DEVICE USING THE SAME | NR2C2, NR2F2, NR2E1 | LMNA 4588/4885THRB 2006/4885CA2 761/4885 |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | IFNG, IRF3, IFNAR1 | LMNA 3209/4885THRB 3455/4885CA2 4467/4885 |
| US-20180251468-A1 | Ionic Liquid, Lubricating Agent, and Magnetic Recording Medium | MUC1, JAK1, JAK3 | LMNA 2468/4885THRB 3275/4885CA2 507/4885 |
| US-20150353558-A1 | Ionic Liquid, Lubricating Agent, and Magnetic Recording Medium | MUC1, JAK1, JAK3 | LMNA 2468/4885THRB 3275/4885CA2 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.